P

P

LORD JESUS CHRIST SAYS

“Whatever you ask for in prayer, believe that you have received it, and it will be yours. And when you stand praying, if you hold anything against anyone, forgive them, so that your Father in heaven may forgive you your sins.” Jesus Christ, Mark 11:24-25

20 Jan 2019

STOCK MARKET--Buy Sandur Manganese: SP Tulsian share analysts.


Below is the verbatim transcript of the interview.
Sonia: Wanted to talk about your long term stock idea which is Sandur Manganese. What is the call here?
A: The stock was given by me on September 21, about three months back at Rs 890 and the stock has already given a gain of 38 percent in this three months and still we are keeping the positive bias for the simple reason that there has been Supreme Court judgment yesterday where the exploration of the iron ore is enhanced from 30 million tonne which was capped earlier, to 35 million tonne. If you really take a call on this company, they have mines of iron ore and manganese ore in Sandur in Karnataka near Bellary and largely supplying to JSW Steel and all that.
Company has a reserve of 75 million tonne of iron ore and 8 million tonne of manganese ore, and if you really see when the 2013 – I am just giving a little background, when Supreme Court allowed the empowered committee to fix the cap of production by each company, in fact this company was entitled to produce 16 lakh tonne of iron ore per annum. However, the empowered committee which was appointed by the Supreme Court has allowed them only to explore 11.7 lakh tonne of iron ore per annum; I am talking lakhs not millions. 11.7 lakh tonne per annum and because of the huge reserves the company having at their end with the mining capacity, company produced about 11.8 million tonne closer to the capacity and they produced about 11.5 lakh tonne in FY17 and in the current year that production is likely to get enhanced to 11.7 lakh tonne per annum that is to their permitted capacity because they should not breach the set limit by the empowered committee.
So this is seen as a very big positive because in the course of the increase from 30 million tonne for Karnataka to 35 million tonne, larger portion of that share is going to be received by this company. I would not be surprised to see the capacity enhanced from 11.7 lakh tonne to 16 lakh tonne which was allowed by the Supreme Court but capped by the empowered group of committee. So taking that into account, it is very positive.

19 Jan 2019

STOCK MARKET--Buy HIL; target of Rs 2763: Anand Rathi/Try your luck.


Anand Rathi is bullish on HIL has recommended buy rating on the stock with a target price of Rs 2763 in its research report

Anand Rathi's research report on HIL

Its sharper focus on cost optimisation, solution-centric approach and ramped-up pipe capacities led HIL to report a good performance. Its strong brand, optimised working capital, Parador acquisition and leading position in asbestos-based roofing and AAC blocks are other positives. We retain our Buy recommendation.

Outlook

We believe that HIL, with its leading position, expansion in a high-growth market and its better operating performance, will post a sturdy performance. We, therefore, retain our Buy rating, with a target of `2,763 at a 15x PE on FY20e.

18 Jan 2019

STOCK MARKET--Cadila Healthcare may test Rs 435: Anand Rathi


Cadila Healthcare is one of the top three in gynaecology, respiratory, pain management, CVS and dermatology.
We believe a pick-up in market share of gToprol, launches and the launched Asacol HD (own version) would help maintain Cadila’s margins
and earnings ahead. On the high base, we expect 8 percent and 9 percent CAGRs over FY18-21 in revenue and earnings respectively.
The company expects 40-50 launches annually and is focusing on vaccines and biologics – which could be future growth drivers.
It has strong ANDA pipeline in the US, with 144 filings awaiting approval of which 60+ are Para IV. It launched 20 products in the year,
including g Lialda and gTamiflu and received 77 approvals in FY18, bringing cumulative filings/approvals to 330/186.
The company has recently announced it is considering fund raising proposals of up to Rs 10,000 Cr via QIP & up to Rs 5,000 cr via FCCBs.
We expect 11 percent and 17 percent CAGRs over FY18-20 in revenue & earnings respectively, our target price is based on 21x FY20e EPS of23.30.